Tempus AI annual diluted eps
Diluted EPSBasic EPS
2022
2023
2024
2025
Tempus AI EPS History: Annual & Quarterly (TEM)
Tempus AI's diluted EPS was -$1.41 for fiscal 2025.
View full Tempus AI company overviewTempus AI annual diluted eps history
| Fiscal year | Period ended | Diluted EPS | Basic EPS | Change | Growth |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | -$1.41 | -$1.41 | $4.82 | — |
| 2024 | 2024-12-31 | -$6.23 | -$6.23 | -$2.03 | — |
| 2023 | 2023-12-31 | -$4.20 | -$4.20 | $1.10 | — |
| 2022 | 2022-12-31 | -$5.30 | -$5.30 | — | — |
Tempus AI quarterly diluted eps
Diluted EPSBasic EPS
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Diluted EPS | Basic EPS | Change | YoY change |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $0.03 | $0.03 | $0.28 | — |
| Q1 2026 | 2026-03-31 | -$0.71 | -$0.70 | -$0.31 | — |
| Q3 2025 | 2025-09-30 | -$0.46 | -$0.46 | $0.00 | — |
| Q2 2025 | 2025-06-30 | -$0.25 | -$0.25 | $6.61 | — |
| Q1 2025 | 2025-03-31 | -$0.40 | -$0.40 | $1.07 | — |
| Q3 2024 | 2024-09-30 | -$0.46 | -$0.46 | $0.57 | — |
| Q2 2024 | 2024-06-30 | -$6.86 | -$6.86 | -$5.79 | — |
| Q1 2024 | 2024-03-31 | -$1.47 | -$1.47 | — | — |
| Q3 2023 | 2023-09-30 | -$1.03 | -$1.03 | — | — |
| Q2 2023 | 2023-06-30 | -$1.07 | -$1.07 | — | — |
Tempus AI diluted eps trends
Between the periods ended 2022-12-31 and 2025-12-31, Tempus AI's diluted eps increased from -$5.30 to -$1.41, a change of $3.89. The latest reported quarter, Q2 2026, shows $0.03.
About the metric
What earnings per share (EPS) means
Earnings per share (EPS) shows how much profit or loss is attributable to each common share. Diluted EPS includes the potential effect of convertible securities, options, and other instruments that could increase the share count, while basic EPS uses the weighted-average common shares actually outstanding.
Calculation and source
SEC-reported diluted and basic EPS
TickerStat displays diluted and basic earnings per share from SEC filings. Historical EPS values are adjusted to the current share basis when SEC-reported stock-split conversion ratios are available; they are not analyst estimates or earnings forecasts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Tempus AI source filings ↗Community posts
Tempus secures European IVDR certification for its RNA tumor-profiling assay
Tempus ($TEM) received certification for its xR assay under the European Union’s In Vitro Diagnostic Regulation as a Class C diagnostic device. The certification also covers its quality management system for cancer genomic profiling with ne ...
Tempus gains FDA clearance for mitral-regurgitation screening AI
Tempus AI ($TEM) has received FDA 510(k) clearance for ECG-MR, software that examines standard resting 12-lead electrocardiograms for signs associated with previously undiagnosed moderate or severe mitral regurgitation. It is the company’s ...
Tempus plans disease-focused dataset covering 100,000 whole genomes
Tempus AI ($TEM) launched an initiative to build a research platform linking 100,000 whole-genome sequences with long-term clinical information over several years. The company intends to focus on disease populations and treatment outcomes, ...
